Navigation Links
Pearl Therapeutics Raises $15.5 Million in Private Financing
Date:9/6/2007

business and championed efforts to apply its technologies to unexplored opportunities. Sarvajna Dwivedi, Ph.D., executive vice president of R&D at Pearl, was most recently director of product development at Nektar. He brings 14 years of extensive pulmonary drug development experience across multiple dosage forms to Pearl, having participated in the inception, development and commercialization of major products in his prior scientific, engineering and management roles at GlaxoWellcome, Dura Pharmaceuticals, Alkermes and Nektar.

"We are very pleased to have received strong support from top-tier and sophisticated biopharmaceutical investors," said Mr. Smith. "These funds will enable us to combine commercially validated particle technologies with the drug delivery, formulation, and product development know-how of the Pearl team to create differentiated products with the potential to broadly and effectively address serious respiratory conditions."

"Pearl Therapeutics incorporates a founding management team with a strong track record of success and expertise in pulmonary drug development including the scale up and commercialization of new products based on proprietary particle technologies. We believe Pearl's products offer the potential for improved treatment of a wider population of patients with chronic respiratory disease," said Dr. Young, executive chairman of the Company, on behalf of the company's investors. "Based on my experience in drug delivery and product development, I am excited to have the opportunity to work with this team and company."

"Adrian and Sarvajna have expert backgrounds in developing pulmonary products and we're pleased that our former colleagues will be exploring new applications with our suite of proven particle technologies," Mr. Elam said.

About Pearl Therapeutics, Inc.

Pearl Therapeutics is focused on developing a pipeline of novel and superior products for chronic respiratory disorders, providing patients wit
'/>"/>

SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy raises $223 million in IPO
3. Fusion 2007: CA chief says IT complexity raises risk
4. Inline intellectual property raises legal issues
5. Biotech with Madison ties raises $21M in capital
6. ConjuGon raises $3.3 million to fund clinical trials
7. Nerites raises $1 million to improve medical tech
8. Brady Corp. raises $137 million in public offering
9. aOva Technologies raises $3 million
10. Bush praises Johnson Controls battery tech in Milwaukee visit
11. Anthropology professors blog raises public interest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... law H.R. 83, the Omnibus and Continuing Resolution Appropriations ... hydrocephalus a condition eligible to receive funding through the ... Department of Defense (DoD). The Hydrocephalus Association (HA), working ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... , RICHMOND, Calif. , ... announced today that Edward Lanphier , Sangamo,s president and CEO, will ... and an overview of the company,s business strategy at 9:00 am ... Annual BIO CEO & Investor Conference which will be held in ...
... , , SAN FRANCISCO , ... MERR ) acted as a placement agent in GenVec, Inc.,s (Nasdaq: ... million shares of common stock, and warrants to purchase 4.2 million ... today. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working ...
... , TSX Exchange Symbol: RVX , CALGARY, Feb. 1 ... announced today that the Board of Directors has elected ... of the Bayer HealthCare Executive Committee, to the Board effective ... in 2004 as Chairman of the Bayer HealthCare Executive Committee ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 2Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 3Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors 4
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Yale University have discovered that a specialized receptor, normally ... throughout the body, sensing small molecules created by microbes ... by increasing blood pressure. The finding suggests that gut ... system for maintaining a stable blood pressure. A ...
... Korea Advanced Institute of Science and Technology (KAIST) and ... on February 20th, 2013 the Master Research and Collaboration ... development of carbon management between the two entities. ... of the Memorandum of Understanding (MOU) between KAIST and ...
... from Michigan State University have successfully engineered a plant with ... as well as lead to improved animal feeds. The ... Cell , the journal of the American Society of Plant ... in oil production to engineer a plant that stores lipids ...
Cached Biology News:Blood vessels 'sniff' gut microbes to regulate blood pressure 2Blood vessels 'sniff' gut microbes to regulate blood pressure 3Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2'Fat worms' inch scientists toward better biofuel production 2
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
...
... The OneSTrEP Protein Interaction Kit ... single step method to isolate intact ... require tedious optimization or multiple purification ... the highly selective StrepTactin Superflow Column ...
Biology Products: